Personalized Medicine in Acromegaly: The ACROFAST Study
Author Information
Author(s): Marques-Pamies Montserrat, Gil Joan, Sampedro-Nuñez Miguel, Valassi Elena, Biagetti Betina, Giménez-Palop Olga, Hernández Marta, Martínez Silvia, Carrato Cristina, Villar-Taibo Rocío, Araujo-Castro Marta, Blanco Concepción, Simón-Muela Inmaculada, Simó-Servat Andreu, Xifra Gemma, Vázquez Federico, Pavón Isabel, Rosado José Antonio, García-Centeno Rogelio, Zavala Roxana, Hanzu Felicia Alexandra, Mora Mireia, Aulinas Anna, Vilarrasa Nuria, Librizzi Soledad, Calatayud María, de Miguel Paz, Alvarez-Escola Cristina, Picó Antonio, Salinas Isabel, Fajardo-Montañana Carmen, Cámara Rosa, Bernabéu Ignacio, Jordà Mireia, Webb Susan M, Marazuela Mónica, Puig-Domingo Manel
Primary Institution: Instituto de Salud Carlos III
Hypothesis
The personalized protocol would be more efficient for medical therapy of acromegaly compared to standard treatment.
Conclusion
Personalized medicine is feasible and allows a higher number of patients to achieve control in a shorter period of time.
Supporting Evidence
- More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%).
- Patients from the personalized arm were controlled in a shorter period of time.
- The hazard ratio for achieving hormonal control adjusted by age and sex was 2.53.
Takeaway
This study shows that using a personalized approach to treat acromegaly helps more patients get better faster than the usual method.
Methodology
A prospective trial comparing personalized treatment based on biomarkers to standard treatment in 21 university hospitals over 12 months.
Potential Biases
Potential bias due to non-randomized design and exclusion of patients.
Limitations
The study was not randomized, and there were more exclusions in the personalized group.
Participant Demographics
Participants included adults aged 18-80 with acromegaly, both newly diagnosed and postsurgical noncured cases.
Statistical Information
P-Value
p<0.05
Confidence Interval
CI, 1.30-4.80
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website